Junshi Biosciences (688180.SH): Toripalimab Injection's New Indication Included in National Medical Insurance Catalog

Zhitong Finance APP News, Junshi Biosciences (688180.SH) announced that recently, the indication of the company's product toripalimab injection (trade name: Tuoyi, product code: JS001) in combination with disitamab vedotin for HER2-expressing locally advanced or metastatic urothelial carcinoma has been successfully included in the Class B scope of the "National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2026)" (referred to as the "National Medical Insurance Catalog"). The new version of the National Medical Insurance Catalog will be officially implemented starting January 1, 2027. As of the disclosure date of the announcement, all 13 indications of Tuoyi approved for marketing in mainland China have been included in the National Medical Insurance Catalog, making it the only anti-PD-1 monoclonal antibody drug in the catalog for the treatment of triple-negative breast cancer, melanoma, first-line renal cancer, and first-line urothelial carcinoma.